All stock lists
SELLAS Life Sciences Group, Inc (SLS)
NASDAQ: SLS · Real-Time Price · USD
Healthcare · Biotechnology
$14.80-$3.15 (-17.55%)
Insider Score
––Not scored
SLS Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
SLS Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| SG&A Expense | $4.28 M | $4.36 M | $4.12 M | $3.52 M | $2.87 M | — |
| R&D Expense | $7.03 M | $6.27 M | $5.13 M | $4.73 M | $4.22 M | — |
| Operating Expenses | $11.31 M | $10.63 M | $9.25 M | $8.26 M | $7.08 M | — |
| Operating Income | -$11.31 M | -$10.63 M | -$9.25 M | -$8.26 M | -$7.08 M | — |
| Pretax Income | -$10.09 M | -$9.61 M | -$8.41 M | -$7.66 M | -$6.79 M | — |
| Tax Provision | — | — | — | — | — | — |
| Net Income | -$10.09 M | -$9.61 M | -$8.41 M | -$7.66 M | -$6.79 M | — |
| EPS (Basic) | -$0.05 | -$0.05 | -$0.05 | — | -$0.06 | -$0.07 |
| EPS (Diluted) | -$0.05 | -$0.05 | -$0.05 | — | -$0.06 | -$0.07 |
| Shares Outstanding | 202.44 M | 189.18 M | 172.48 M | — | 108.40 M | 98.56 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.
